Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chung-Feng Huang

Showing results (1-10 of 286) with videos related to

Pageof 29
Sort By:
Expert Opinion on Pharmacotherapy|November 1, 2017
Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developmentsChung-Feng Huang, Ming-Lung Yu
Clinical and Molecular Hepatology|March 20, 2020
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapyChung-Feng Huang, Ming-Lung Yu
Clinical and Molecular Hepatology|February 12, 2019
Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?Chung-Feng Huang, Ming-Lung Yu
Expert Review of Anti-Infective Therapy|January 11, 2021
Elbasvir and grazoprevir for the treatment of hepatitis CSzu-Jen Wang, Chung-Feng Huang, Ming-Lung Yu
The Kaohsiung Journal of Medical Sciences|January 3, 2012
Chronic hepatitis C infection in the elderlyChung-Feng Huang, Wan-Long Chuang, Ming-Lung Yu
Journal of the Formosan Medical Association = Taiwan Yi Zhi|October 26, 2025
HCV elimination in hyperendemic areas: Experiences in TaiwanChia-Yen Dai, Chung-Feng Huang, Wan-Long Chuang, et al.
The Journal of Infectious Diseases|September 13, 2023
HCV Microelimination for High-risk Special PopulationsChung-Feng Huang, Guan-Jhou Chen, Chien-Ching Hung, et al.
Clinical and Molecular Hepatology|April 26, 2024
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradicationChung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, et al.
Medicine|November 29, 2016
Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case reportChung-Feng Huang, Tyng-Yuan Jang, Po-Liang Lu, et al.
The Kaohsiung Journal of Medical Sciences|December 10, 2025
Metabolic Dysfunction-Associated Steatotic Liver Disease After Hepatitis C Virus CureChung-Feng Huang, Jee-Fu Huang, Ming-Lung Yu, et al.
Pageof 29

Showing results (1-10 of 286) with videos related to

Sort By:
Pageof 29
Expert Opinion on Pharmacotherapy|November 1, 2017
Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developmentsChung-Feng Huang, Ming-Lung Yu
Clinical and Molecular Hepatology|March 20, 2020
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapyChung-Feng Huang, Ming-Lung Yu
Clinical and Molecular Hepatology|February 12, 2019
Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?Chung-Feng Huang, Ming-Lung Yu
Expert Review of Anti-Infective Therapy|January 11, 2021
Elbasvir and grazoprevir for the treatment of hepatitis CSzu-Jen Wang, Chung-Feng Huang, Ming-Lung Yu
The Kaohsiung Journal of Medical Sciences|January 3, 2012
Chronic hepatitis C infection in the elderlyChung-Feng Huang, Wan-Long Chuang, Ming-Lung Yu
Journal of the Formosan Medical Association = Taiwan Yi Zhi|October 26, 2025
HCV elimination in hyperendemic areas: Experiences in TaiwanChia-Yen Dai, Chung-Feng Huang, Wan-Long Chuang, et al.
The Journal of Infectious Diseases|September 13, 2023
HCV Microelimination for High-risk Special PopulationsChung-Feng Huang, Guan-Jhou Chen, Chien-Ching Hung, et al.
Clinical and Molecular Hepatology|April 26, 2024
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradicationChung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, et al.
Medicine|November 29, 2016
Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case reportChung-Feng Huang, Tyng-Yuan Jang, Po-Liang Lu, et al.
The Kaohsiung Journal of Medical Sciences|December 10, 2025
Metabolic Dysfunction-Associated Steatotic Liver Disease After Hepatitis C Virus CureChung-Feng Huang, Jee-Fu Huang, Ming-Lung Yu, et al.
Pageof 29